Catalyst Dossier · compiled by CeliA 🧫

BioLineRx Ltd. (BLRX)

Pharmaceutical Preparations · market cap $15M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BioLineRx (BLRX) is a small Israeli drug development company with 28 employees and a $15M market cap, trading on both NASDAQ and the Tel Aviv Stock Exchange. Its lead asset, BL-8040 (1.25 mg/kg + G-CSF), is in Phase 3 for Multiple Myeloma, with a broader pipeline spanning Phase 2 programs in schizophrenia, aplastic anemia, ulcerative colitis, AML, pancreatic adenocarcinoma, celiac disease, and acute pain. The next near-term event is an earnings release on August 13, 2026.

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
BL-1020	Phase 2	Schizophrenia
horse anti-thymocyte globulin (hATG)	Phase 2	Aplastic Anemia
BL-8040 1.25 mg/kg + G-CSF	Phase 3	Multiple Myeloma
BL-7040	Phase 2	Ulcerative Colitis
Morphine	Phase 2	Acute Pain
BL - 1020	Phase 2	Schizophrenia
BL 1020 High Dose	Phase 2	Schizophrenia
Ara-C	Phase 2	Acute Myeloid Leukemia
BL-8040	Phase 2	Metastatic Pancreatic Adenocarcinoma
BL-7010	Phase 2	Celiac Disease

Price & technical context

3-month

-7.2%

6-month

-14.6%

12-month

-33.2%

52-wk range

$2.18–$4.44

vs 50-day MA

-14.7%

vs 200-day MA

-11.3%

Realized vol

60.7%

Max drawdown

-93.7%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BLRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.